Elyse Stock - Nov 25, 2021 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd. (BHVN)

Role: Chief Medical Officer
Signature: /s/ Jim Engelhart, Attorney-in-fact
Stock symbol: BHVN
Transactions as of: Nov 25, 2021
Transactions value $: -$184,764
Form type: 4
Date filed: 11/26/2021, 03:33 PM
Next filing: Dec 16, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BHVN	Common Shares	Options Exercise	$0	+3.38K	+59.3%	$0.00	9.07K	Nov 25, 2021	Direct
transaction	BHVN	Common Shares	Tax liability	-$185K	-1.6K	-17.64%	$115.55^*	7.47K	Nov 25, 2021	Direct	F1
holding	BHVN	Common Shares						2.19K	Nov 25, 2021	By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BHVN	Restricted Share Unit Award	Options Exercise	$0	-3.38K	-50%	$0.00	3.38K	Nov 25, 2021	Common Shares	3.38K		Direct	F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.
F2	Each restricted share unit represents the contingent right to receive one common share of the issuer.
F3	The reporting person was granted 13,500 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date.
F4	Not applicable.